EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy

Mike Wenzel iD, Benedikt Hoeh, Carolin Siech, Florestan Koll, Clara Humke, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Severine Banek, Felix K H Chun, Philipp Mandel

European Journal of Nuclear Medicine and Molecular Imaging · 2025-05 · 52 (6) · 2015-2022

DOI: 10.1007/s00259-025-07076-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 13.01.2025. Verfasst von Mike Wenzel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radioisotopes, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition (ARPI) and taxan-based chemotherapy. However, its effect in taxan-naïve patients is under current investigation.

Methods

We relied on the FRAMCAP database to elaborate Lu-PSMA therapy outcomes of progression-free (PFS) and overall (OS) in taxan-naïve mCRPC patients after previous ARPI treatment. Comparison was made against current standard of care with ARPI or docetaxel, irrespective of the previous used staging modality.

Results

Of 269 patients, 11% received Lu-PSMA in first/second-line mCRPC vs. 57% ARPI vs. 33% docetaxel. Mostly no significant baseline differences between Lu-PSMA and ARPI patients were observed, while Lu-PSMA patients were significantly older, received less systematic treatments and ECOG1-2 proportions were higher, relative to docetaxel patients. In PFS (13.3 vs. 8.2 months, hazard ratio [HR]: 0.70, p = 0.16) and OS analyses (68.9 vs. 39.1 months, HR: 0.64, p = 0.2), Lu-PSMA was numerically more favorable than ARPI. In additional multivariable Cox regression models, Lu-PSMA was significant better regarding PFS and OS, relative to ARPI (both p < 0.05). Compared to docetaxel, also significant better PFS (13.3 vs. 8.1 months, HR: 0.46) and OS (68.9 vs. 27.3 months, HR: 0.34, both p < 0.01) was observed for Lu-PSMA treatment. The OS advantage was also observed after multivariable adjustment ( p < 0.01).

Conclusion

This retrospective single-center study including a substantial proportion of patients with treatment preference for Lu-PSMA suggests that Lu-PSMA therapy provides significantly more favorable PFS and OS outcomes in taxan-naïve mCRPC patients after previous ARPI treatment, relative to ARPI or docetaxel treatment and may be considered as an early mCRPC treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumRadioisotopesGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleAgedMiddle AgedNeoplasm MetastasisTaxoidsAged, 80 and overTreatment OutcomeRetrospective StudiesRadiopharmaceuticals

Stichwörter der Autor:innen

Lu-177MCRPCOSPFSSurvival

Substanzen

LutetiumRadioisotopesLutetium-177TaxoidsGlutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
  • Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt Am Main, Frankfurt, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Mike Wenzel

Förderung

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Zitieren

APA

Wenzel, M., Hoeh, B., Siech, C., Koll, F., Humke, C., Groener, D., Steuber, T., Graefen, M., Maurer, T., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging, 52(6), 2015-2022. https://doi.org/10.1007/s00259-025-07076-7

Vancouver

Wenzel M, Hoeh B, Siech C, Koll F, Humke C, Groener D, et al. Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(6):2015-2022. doi:10.1007/s00259-025-07076-7

BibTeX
@article{Wenzel2025,
  author = {Wenzel, Mike and Hoeh, Benedikt and Siech, Carolin and Koll, Florestan and Humke, Clara and Groener, Daniel and Steuber, Thomas and Graefen, Markus and Maurer, Tobias and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {6},
  pages = {2015--2022},
  doi = {10.1007/s00259-025-07076-7}
}
Kostenlos starten →